Brugada Syndrome Market Size Worth $2.38 Billion By 2032 | CAGR: 5.7%

The global brugada syndrome market size is expected to reach USD 2.38 billion by 2032, according to a new study by Polaris Market Research. The report “Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology, Genetic testing, Others); By Treatment; By End-User; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors driving the worldwide Brugada syndrome treatment market include an increase in the incidence of the disease, an increase in healthcare spending, an increase in therapeutic demand, advancements in diagnostic technology, and increased government activities to raise awareness. Other reasons that contribute to market expansion include the influence of addiction to smoking, changes in lifestyle, and western culture among adults. Furthermore, exposure to hazardous chemicals and environmental pollution drives market expansion.

According to World Health Organization (WHO) estimates, as of 2019, 17.9 million people died as a result of cardiovascular diseases, accounting for more than 32% of all global fatalities. Furthermore, heart attacks and stroke account for approximately 85% of CVD-related fatalities.

According to The National Organization for Rare Disorders, the frequency of Brugada Syndrome in the United States was projected to be 5 in 10,000 persons in 2019. Furthermore, increased awareness of genetic disorders, as well as a burgeoning pharmaceutical and biotechnology sector, will provide attractive growth opportunities for the market throughout the forecast period.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market/request-for-sample

The demand for heart transplantation has increased considerably in recent years due to a rise in the prevalence of heart failure. However, the failure to meet current demand has resulted in a global scarcity of eligible organs for transplantation. According to the National Database of the Health Coffers and Services Administration of the United States, there were around 4150 campaigners on the heart transplant staying list, as of March 2020.

Brugada syndrome has progressed from an uncommon disorder to the second biggest cause of death among young adults in some countries, after only vehicle accidents. The syndrome, which is electrocardiographically characterized by distinct Pulmonary hypertension in the right precordial leads, is associated with a considerable risk of sudden cardiac death in young and otherwise healthy adults, but less typically in newborns and children.

Brugada Syndrome Market Report Highlights

• The hospital & clinics sector segment has contributed immensely due to the availability and accessibility of novel therapies and equipment.
• Implantable cardioverter defibrillator treatment is expected to witness significant growth over the forecast period owing to wide use of this treatment in BrS. It is known to be a significant cause of sudden cardiac mortality in young people.
• North America dominates the revenue share and is primarily driven by the rising use of electrocardiograms, electrophysiology (EP) tests for illness diagnosis, and a large population base diagnosed with heart-related ailments.
• The global players include Abbott, Boehringer Ingelheim, Catalyst Pharmaceuticals, Ionis Pharmaceuticals, Leadiant Biosciences, Natera, Novo Nordisk, Pfizer, PTC Therapeutics, Roche, Salarius Pharmaceuticals, Takeda Pharmaceuticals, Novartis.

Polaris Market Research has segmented the Brugada market report based on diagnosis, treatment, end-use, and region:

Brugada Syndrome, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

• Electrocardiogram
• Electrophysiology test
• Genetic testing
• Others

Brugada Syndrome, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

• Implantable cardioverter defibrillator
• Drug Therapy
  • Antiarrhythmic Drugs
  • Psychotropic Drugs
  • Anesthetics/Analgesics
• Others

Brugada Syndrome, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals and clinics
• Surgical centers
• Diagnostic centers
• Others

Brugada Syndrome, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa